The 3 analysts offering 12-month price forecasts for Actinium Pharmaceuticals Inc have a median target of 40.00, with a high estimate of 65.00 and a low estimate of 25.00. The median estimate represents a +418.81% increase from the last price of 7.71.
The current consensus among 4 polled investment analysts is to Buy stock in Actinium Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.40
Reporting Date Mar 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.